SAB Biotherapeutics, Inc. SABS
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -10.43%
- 1 year
- +11.30%
- Open
- 3.20
- Prev close
- 3.23
- Mkt cap
- 304.80M
- Vol
- 741.05K
- Avg vol
- 536.84K
- EPS
- -1.29
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.11
- High
- 3.37
- Forward P/E
- -1.56
- Beta
- 0.64
- Short ratio
- 1.22
- Inst. own
- 34.25%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 3.29
- 200-d avg
- 3.35
- 1y target
- 12.40
News
3 days ago globenewswire.com
SAB BIO to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5, 2026, 08:30 AM ET
MIAMI, Oct. 29, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1…
1 week ago marketbeat.com
SAB Biotherapeutics Highlights Diabetes Trial Progress, Human Antibody Platform
Executives from Healios and SAB Biotherapeutics NASDAQ: SABS outlined their approaches to developing scalable biologic therapies during a Chardan discussion focused on complex treatments designed for…
2 weeks ago globenewswire.com
SAB BIO to Participate in Chardan 10th Annual Healthcare Conference
MIAMI, Oct. 14, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1…
-
2 weeks ago benzinga.com
FDA Provides Fast Track Designation SAB Biotherapeutics' SAB-142 To Treat Stage 3 Type 1 Diabetes
SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune…
2 weeks ago globenewswire.com
SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes
Fast Track designation recognizes the potential of SAB-142 to address an unmet medical need for people with Stage 3 type 1 diabetes
1 month ago globenewswire.com
SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress
MIAMI, Oct. 01, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1…
1 month ago defenseworld.net
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock Rated “Moderate Buy” by Sell-Side Analysts
Shares of SAB Biotherapeutics, Inc. (NASDAQ: SABS - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eleven ratings firms that are covering the stock, MarketBeat.com…
1 month ago globenewswire.com
SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes
MIAMI, Sept. 22, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1…
1 month ago seekingalpha.com
SAB Biotherapeutics, Inc. (SABS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
SAB Biotherapeutics, Inc. (SABS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
2 months ago globenewswire.com
SAB BIO to Participate in Upcoming Investor Conferences
MIAMI, Sept. 01, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1…
2 months ago defenseworld.net
375,000 Shares in SAB Biotherapeutics, Inc. $SABS Purchased by AWM Investment Company Inc.
AWM Investment Company Inc. purchased a new position in SAB Biotherapeutics, Inc. (NASDAQ: SABS) during the undefined quarter, according to its most recent filing with the Securities and Exchange…
2 months ago marketbeat.com
SAB Biotherapeutics Q2 Earnings Call Highlights
SAB Biotherapeutics NASDAQ: SABS said its registrational Phase IIb SAFEGUARD trial of SAB-142 in newly diagnosed Stage 3 Type 1 diabetes remains on track to complete enrollment in the fourth quarter…
2 months ago globenewswire.com
SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights
Over 60 clinical sites activated in registrational SAFEGUARD study of SAB-142 in Stage 3 new onset type 1 diabetes; Enrollment remains on track for completion in Q4 2026, with topline data expected…
3 months ago defenseworld.net
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Shares of SAB Biotherapeutics, Inc. (NASDAQ: SABS - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eleven research firms that are currently covering the firm,…
-
3 months ago benzinga.com
SAB Biotherapeutics Receives Breakthrough T1D Grant To Advance SAB-142 Study In Newly Diagnosed Type 1 Diabetes
Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a…
3 months ago globenewswire.com
Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes
MIAMI, July 07, 2026 (GLOBE NEWSWIRE) -- Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage…
-
4 months ago benzinga.com
Barclays Initiates Coverage On SAB Biotherapeutics with Overweight Rating, Announces Price Target of $13
Barclays analyst Eliana Merle initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Overweight rating and announces Price Target of $13.
-
4 months ago benzinga.com
Chardan Capital Maintains Buy on SAB Biotherapeutics, Raises Price Target to $16
Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and raises the price target from $14 to $16.
4 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
4 months ago benzinga.com
Paychex To Rally More Than 39%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on top names. See all rating changes on our analyst ratings page. Barclays, Wells Fargo, Piper Sandler, Leerink Partners, Truist Securities, and…
-
4 months ago benzinga.com
Leerink Partners Maintains Outperform on SAB Biotherapeutics, Raises Price Target to $12
Leerink Partners analyst Thomas Smith maintains SAB Biotherapeutics (NASDAQ:SABS) with a Outperform and raises the price target from $7 to $12.
-
4 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on SAB Biotherapeutics, Maintains $10 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $10 price target.
5 months ago globenewswire.com
SAB BIO to Present Data on SAB-142 at The American Diabetes Association's 2026 Scientific Sessions and FOCIS 2026 Annual Meeting
Data will highlight deeper mechanistic insights and long-term dosing potential of SAB-142, a fully human multi-specific ATG for newly diagnosed Stage 3 T1D Data will highlight deeper mechanistic…
-
5 months ago benzinga.com
Citigroup Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $11
Citigroup analyst Samantha Semenkow initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Buy rating and announces Price Target of $11.
5 months ago benzinga.com
This QuickLogic Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday
Wall Street analysts changed outlook on top names. See full ratings page for upgrades, downgrades, and initiations. Analysts view QUIK stock positively.
-
5 months ago benzinga.com
Jefferies Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $11
Jefferies analyst Roger Song initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Buy rating and announces Price Target of $11.
5 months ago marketbeat.com
SAB Biotherapeutics Q1 Earnings Call Highlights
SAB Biotherapeutics NASDAQ: SABS said its lead type 1 diabetes candidate, SAB-142, remains on track in a registrational Phase 2b trial, as the clinical-stage biopharmaceutical company reported a…
-
5 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on SAB Biotherapeutics, Raises Price Target to $10
HC Wainwright & Co. analyst Emily Bodnar maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and raises the price target from $7 to $10.
-
5 months ago benzinga.com
Full Transcript: SAB Biotherapeutics Q1 2026 Earnings Call
Full Transcript: SAB Biotherapeutics Q1 2026 Earnings Call
-
5 months ago benzinga.com
SAB Biotherapeutics Q1 EPS $(0.35) Misses $(0.20) Estimate.
SAB Biotherapeutics (NASDAQ:SABS) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.20) by 75 percent. This is a 37.5 percent increase over losses of…
5 months ago globenewswire.com
SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights
Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027
-
5 months ago benzinga.com
Rodman & Renshaw Reiterates Buy on SAB Biotherapeutics, Maintains $13 Price Target
Rodman & Renshaw analyst Seema Sheoran reiterates SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $13 price target.
6 months ago globenewswire.com
SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET
MIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1…
-
6 months ago benzinga.com
Emergent BioSolutions Signs Multi-Year, ~$50M Agreement With SAB Biotherapeutics For Development And Manufacturing Of SAB-142, SAB's Lead Program In Clinical Development For Autoimmune Type 1 Diabetes
The executed agreement is valued at approximately $50 million, of which $36 million is contingent on future regulatory approval and downstream milestones.Under the terms of the agreement, Emergent…
6 months ago globenewswire.com
SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026
All 4 T1D participants receiving SAB-142 showed C-peptide preservation with 3 of the 4 participants showing a super responder profile concomitant with T cell exhaustion T1D participants receiving…
6 months ago seekingalpha.com
SAB Biotherapeutics Looks Undervalued If SAB-142 Delivers In Type 1 Diabetes
SAB Biotherapeutics is a clinical-stage biotech centered on SAB-142, a disease-modifying T1D candidate targeting both stage 2 and stage 3 patients. SAB-142 may preserve beta-cell function and…
-
6 months ago benzinga.com
SAB Biotherapeutics To Present Oral Presentation, Multiple Poster Presentations At 21st Immunology of Diabetes Society Congress On Its SAB-142 Program
SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune…
-
7 months ago benzinga.com
SAB Biotherapeutics Launches Public Stock Offering To Fund Development Of Type 1 Diabetes Therapy; No Terms Disclosed
SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune…
-
7 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on SAB Biotherapeutics, Lowers Price Target to $7
HC Wainwright & Co. analyst Emily Bodnar maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and lowers the price target from $9 to $7.
-
7 months ago benzinga.com
SAB Biotherapeutics Announces Additional Data From Phase 1 HUman Anti-Thymocyte Biologic In First-In-MAN Clinical Trial Of SAB-142; Results Demonstrated Early Signals Of C-peptide Preservation
T1D key opinion leader, Michael J. Haller, MD, provided a recorded webinar reviewing the SAB-142 Phase 1 dataMIAMI, March 10, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a…
-
9 months ago benzinga.com
UBS Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $7
UBS analyst Michael Yee initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Buy rating and announces Price Target of $7.
-
10 months ago benzinga.com
Guggenheim Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $15
Guggenheim analyst Yatin Suneja initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Buy rating and announces Price Target of $15.
-
10 months ago benzinga.com
Chardan Capital Maintains Buy on SAB Biotherapeutics, Maintains $12 Price Target
Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $12 price target.
-
10 months ago benzinga.com
SAB Biotherapeutics Announces Confirmatory Data From Phase 1 Trial Of SAB-142 In Single- And Multiple-Ascending Dose Among Healthy Volunteers, Including Re-Dosed Cohort, And T1D Patients
Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all cohorts, including redosed healthy volunteers Study results support the chronic dosing…
10 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
10 months ago benzinga.com
SAB Biotherapeutics To Highlight Data Showcasing Progress In Development Of SAB-142 At ATTD-Asia
SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases,…
-
11 months ago benzinga.com
Chardan Capital Maintains Buy on SAB Biotherapeutics, Maintains $12 Price Target
Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $12 price target.
-
12 months ago benzinga.com
SAB Biotherapeutics To Present Phase 1 Data Demonstrating SAB-142's Multi-Specific Mechanism Of Action, Sustained Immunomodulation, Favorable Safety Profile Without Serum Sickness Or Anti-Drug Antibodies, And A Novel Pharmacokinetic Assay For Measuring The Drug
SAb Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases,…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session